TY - JOUR
T1 - Association of polymorphism of TLR4 and CD14 genes with gastroduodenal diseases in Japan
AU - Tahara, T.
AU - Arisawa, T.
AU - Shibata, T.
AU - Hirata, I.
AU - Nakano, H.
PY - 2007/6
Y1 - 2007/6
N2 - Background: Host genetic factors may play a key role in determining the long-term outcome of the Helicobacter pylori infection. Toll like receptor 4(TLR4) and CD14-mediated recognition of lipo-polysaccharide (LPS) is required for efficient recognition of Gram-negative bacterial infections. Aims: We investigated the effects of common polymorphisms of TLR4 Asp299Gly, Thr399Ile and CD14 promoter -C159T on the risk of gastric cancer including its subtypes and clinicopathologic features. We also investigated the effects of these polymorphisms on histologic degree of H. pylori induced gastritis. Subjects: The study was performed in 149 gastric cancer(GC) cases [mean age 64.0 ±12.4, M:F = 109:40] and 94 patients without evidence of GC (mean age 64.1 ±12.3, M:F = 65:25, Peptic ulcer diseases = 43.6%, gastritis = 56.4%) as the control group. Methods: TLR4 Asp299Gly, Thr399Ile and CD14 promoter - C159T were determined by PCR-RFLP in all the patients. Gastritis scores of non-cancerous gastric mucosa were assessed according to the updated Sydney system in H. pylori-positive subjects(n = 174). Results: The frequencies of CD14-260 TT and T carrier were significantly lower in patents with intestinal type gastric cancer than in controls (OR = 0.31;95% CI = 0.12-0.78, OR = 0.38; 95% CI = 0.18-0.81, respectively) Compared with patients older than 61 years, the atrophy score in antrum was significantly lower in TT and CT patients.TLR4 Asp299Gly, Thr399Ile were not detected in all the patients. Conclusion: Our data suggest that CD14 promoter-159TT and T carrier were associated with lower risk of developing gastric mucosal atrophy in H. pylori infected patients more than 61 years of age, and these genotypes may reduce the risk of intestinal type gastric cancer and TLR4 Asp299Gly, Thr399Ile are very rare in the Japanese population.
AB - Background: Host genetic factors may play a key role in determining the long-term outcome of the Helicobacter pylori infection. Toll like receptor 4(TLR4) and CD14-mediated recognition of lipo-polysaccharide (LPS) is required for efficient recognition of Gram-negative bacterial infections. Aims: We investigated the effects of common polymorphisms of TLR4 Asp299Gly, Thr399Ile and CD14 promoter -C159T on the risk of gastric cancer including its subtypes and clinicopathologic features. We also investigated the effects of these polymorphisms on histologic degree of H. pylori induced gastritis. Subjects: The study was performed in 149 gastric cancer(GC) cases [mean age 64.0 ±12.4, M:F = 109:40] and 94 patients without evidence of GC (mean age 64.1 ±12.3, M:F = 65:25, Peptic ulcer diseases = 43.6%, gastritis = 56.4%) as the control group. Methods: TLR4 Asp299Gly, Thr399Ile and CD14 promoter - C159T were determined by PCR-RFLP in all the patients. Gastritis scores of non-cancerous gastric mucosa were assessed according to the updated Sydney system in H. pylori-positive subjects(n = 174). Results: The frequencies of CD14-260 TT and T carrier were significantly lower in patents with intestinal type gastric cancer than in controls (OR = 0.31;95% CI = 0.12-0.78, OR = 0.38; 95% CI = 0.18-0.81, respectively) Compared with patients older than 61 years, the atrophy score in antrum was significantly lower in TT and CT patients.TLR4 Asp299Gly, Thr399Ile were not detected in all the patients. Conclusion: Our data suggest that CD14 promoter-159TT and T carrier were associated with lower risk of developing gastric mucosal atrophy in H. pylori infected patients more than 61 years of age, and these genotypes may reduce the risk of intestinal type gastric cancer and TLR4 Asp299Gly, Thr399Ile are very rare in the Japanese population.
UR - http://www.scopus.com/inward/record.url?scp=34347380128&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34347380128&partnerID=8YFLogxK
U2 - 10.1007/s10787-006-1567-8
DO - 10.1007/s10787-006-1567-8
M3 - Article
C2 - 19847953
AN - SCOPUS:34347380128
SN - 0925-4692
VL - 15
SP - 124
EP - 128
JO - Inflammopharmacology
JF - Inflammopharmacology
IS - 3
ER -